Get the Stockscreener App
2.59
15.96%
-0.54
Soligenix Inc stock is traded at $2.59, with a volume of 10.19M.
It is down -15.96% in the last 24 hours and down -16.76% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$3.13
Open:
$3.33
24h Volume:
10.19M
Relative Volume:
51.63
Market Cap:
$6.62M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.3426
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
-26.72%
1M Performance:
-16.76%
6M Performance:
-64.59%
1Y Performance:
-80.38%
1-Day Range:
$2.43
$3.44
1-Week Range:
$2.43
$3.68
52-Week Range:
$1.8301
$14.92
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
2.5801 | 6.62M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.99 | 106.45B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
705.98 | 77.86B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
674.80 | 40.09B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.90 | 33.16B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
116.64 | 27.70B | 3.30B | -501.07M | 1.03B | -2.1146 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PR Newswire
EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year - Yahoo Finance
Cutaneous T-cell Lymphoma Market on Track for Major Expansion - openPR
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - StockTitan
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte - Citybuzz
Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial - Yahoo Finance
Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL - Nasdaq
Soligenix initiates confirmatory Phase 3 trial of HyBryte - Yahoo Finance
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway - Smartkarma
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway… - Zacks Small Cap Research
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - AOL
Soligenix, Inc. Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PR Newswire
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
Soligenix's HyBryte™ Shows 3x Better Response Rate vs Valchlor® in Rare Disease Trial - StockTitan
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - The Malaysian Reserve
Soligenix (STU:DOA) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs - Nasdaq
Soligenix Advances Promising Treatments for Rare Diseases and Public Health Threats - Citybuzz
Soligenix Announces Recent Accomplishments And Third Quarter 202 - GuruFocus.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusqueti - GuruFocus.com
Soligenix Launches European Advisory Board for Phase 3 HyBryte CTCL Trial - Dermatology Times
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PR Newswire
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - The Malaysian Reserve
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels - AOL
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease - Marketscreener.com
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024 - MSN
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) - Yahoo Finance
Soligenix Inc. (SNGX) Quarterly 10-Q Report - Quartz
SEC Form 424B3 filed by Soligenix Inc. - Quantisnow
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - citybiz
Soligenix Reports Q3 Loss, Advances Clinical Pipeline with $9.8M Cash Position | SNGX Stock News - StockTitan
Soligenix Granted FDA Orphan Drug Designation For SuVax Active Ingredient - Contract Pharma
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference - GlobeNewswire
Soligenix gains Hong Kong patent for synthetic hypericin - Investing.com India
Soligenix to Present at Upcoming Conferences - GuruFocus.com
Soligenix gains Hong Kong patent for synthetic hypericin By Investing.com - Investing.com Nigeria
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - Lelezard
Soligenix Invited to Present at Upcoming Investor Conferences - StockTitan
Soligenix secures amended loan terms with Pontifax Medison - Investing.com India
Soligenix secures amended loan terms with Pontifax Medison By Investing.com - Investing.com UK
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference - PR Newswire
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.37%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):